Michael Täger

Title: Michael Täger: Innovator in Pharmaceutical Research

Introduction

Michael Täger is a notable inventor based in Heinrichsberg, Germany. He has made significant contributions to the field of pharmaceutical research, particularly in the development of therapies for inflammatory and neurodegenerative diseases. With a total of 3 patents, Täger's work reflects his commitment to advancing medical science.

Latest Patents

Among his latest patents, Täger has developed dual-use peptidase inhibitors as prodrugs for the therapy of inflammatory and other diseases. This innovation includes compounds of the general formulae (1) and (2). Additionally, he has created a drug preparation comprising α-lipoic acid, ambroxol, and/or inhibitors of the angiotensin-converting enzyme (ACE) for the treatment of neurodegenerative diseases. This drug composition aims to provide effective prevention and therapy for such conditions.

Career Highlights

Throughout his career, Täger has worked with several prominent companies in the pharmaceutical industry. Notably, he has been associated with Keyneurotek Pharmaceuticals AG and Serumwerk Bernburg AG. His work in these organizations has allowed him to contribute to significant advancements in drug development.

Collaborations

Täger has collaborated with esteemed colleagues in his field, including Siegfried Ansorge and Peter Röhnert. These partnerships have further enriched his research and innovation efforts.

Conclusion

Michael Täger's contributions to pharmaceutical research and his innovative patents highlight his role as a key figure in the development of therapies for critical health issues. His work continues to inspire advancements in medical science.